Phaseline

Targets › CDK9

CDK9 (Cyclin-dependent kinase 9): drug programs, companies and trials

3 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when…. (UniProt, P50750)

Open in Phaseline: the race on CDK9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Dinaciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor
CDK1, CDK2, CDK5, CDK9Phase 2Acral Lentiginous Melanoma; Advanced Malignant Solid NeoplasmMar 2027
Sellas Life Sciences GroupSLS009
CDK9 inhibitor
CDK9Phase 1Hematologic MalignanciesDec 2026
National Cancer Institute (NCI)Zotiraciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor
CDK1, CDK2, CDK7, CDK9, FLT3Phase 1Brain TumorAug 2028

Conditions

Brain Tumor (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1) Hematologic Malignancies (1)

Modalities

small molecule (3)

Companies

National Cancer Institute (NCI) (2) Sellas Life Sciences Group (1)

Related targets

CDK1 (2) CDK2 (2) CDK7 (1) FLT3 (1) CDK5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.